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Abstract
Background: Accurate incidence estimates are needed for surveillance of the HIV epidemic. HIV surveillance occurs at
maternal-child health clinics, but it is not known if pregnancy affects HIV incidence testing.
Methods: We used the BED capture immunoassay (BED) and an antibody avidity assay to test longitudinal samples from 51
HIV-infected Ugandan women infected with subtype A, C, D and intersubtype recombinant HIV who were enrolled in the
HIVNET 012 trial (37 baseline samples collected near the time of delivery and 135 follow-up samples collected 3, 4 or 5 years
later). Nineteen of 51 women were also pregnant at the time of one or more of the follow-up visits. The BED assay was
performed according to the manufacturer’s instructions. The avidity assay was performed using a Genetic Systems HIV-1/
HIV-2 + O EIA using 0.1M diethylamine as the chaotropic agent.
Results: During the HIVNET 012 follow-up study, there was no difference in normalized optical density values (OD-n)
obtained with the BED assay or in the avidity test results (%) when women were pregnant (n=20 results) compared to those
obtained when women were not pregnant (n=115; for BED: p=0.9, generalized estimating equations model; for avidity:
p=0.7, Wilcoxon rank sum). In addition, BED and avidity results were almost exactly the same in longitudinal samples from
the 18 women who were pregnant at only one study visit during the follow-up study (p=0.6, paired t-test).
Conclusions: These results from 51 Ugandan women suggest that any changes in the antibody response to HIV infection
that occur during pregnancy are not sufficient to alter results obtained with the BED and avidity assays. Confirmation with
larger studies and with other HIV subtypes is needed.
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Introduction
Accurate HIV incidence estimates are critical for monitoring
the HIV/AIDS epidemic, identifying populations at high risk of
HIV acquisition, targeting prevention efforts, and designing and
evaluating HIV prevention trials. HIV incidence can be assessed
by evaluating seroconversion in longitudinal cohort studies,
modeling trends in serial HIV prevalence, and applying back-
calculation methods to AIDS/HIV surveillance data. However,
each of those approaches has practical and methodological
limitations [1,2]. An alternative approach is to use cross-sectional
surveys in combination with laboratory assays to identify recently-
infected persons. However, the utility of the cross-sectional
approach to HIV incidence determination has been hampered
because currently available laboratory assays misclassify some
chronically-infected persons as recently infected.
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HIV incidence by cross-sectional sampling. Individuals with acute
(pre-seroconversion) HIV infection can be identified by detecting
HIV RNA or HIV antigen in the absence of HIV antibody [3].
However, because the window period of acute HIV infection is
very short (2–3 weeks), very large populations must be tested to
determine HIV incidence using that approach. An alternative
approach is to determine HIV incidence using serologic assays that
are designed to differentiate between individuals with recent vs.
chronic HIV infection (e.g., assays that measure HIV antibody
titer, avidity, isotype, specificity, or the proportion of the antibody
response that is HIV-specific) [4,5]. Those assays generally rely on
use of pre-defined cut-off values to characterize HIV infections as
recent vs. chronic. Unfortunately, the antibody response to HIV
infection varies considerably among individuals. Chronically-
infected individuals with natural or ARV-mediated viral suppres-
sion and individuals with advanced HIV disease may appear
incident using some assays [6]. Misclassification of chronically-
infected individuals as recently infected may also vary among
different HIV subtypes [7].
In this study, we evaluated the impact of pregnancy on the
performance of two serologic assays: the BED-Capture enzyme
immunoassay (BED) [8] and an avidity assay based on the BioRad
1/2+ O ELISA [9]. These assays measure different characteristics
of the immune response to HIV infection. The BED assay
measures the proportion of antibody that is HIV-specific, while the
avidity assay measures how tightly anti-HIV antibodies bind to
target antigens and is not influenced by the amount or proportion
of anti-HIV antibodies in a sample. These assays also differ in the
type of antigens used for antibody detection and characterization.
The BED assay includes antigens from subtypes B and D, as well
as CRF01_AE, while the avidity assay includes antigens from a
broader spectrum of HIV-1 strains, as well as antigens from HIV-
2. Each of these assays is known to misclassify some chronically-
infected individuals as recently infected [10,11]. However, studies
suggest that these assays may be useful for HIV incidence
determination when used in combination along with non-serologic
biomarkers, such as HIV viral load or CD4 cell count [6].
Effective application of these assays to cross-sectional HIV
incidence determination, either alone or in multi-assay algorithms,
requires knowledge of the clinical and demographic factors
associated with misclassification [12]. Misclassification of chron-
ically-infected individuals as recently infected is particularly
problematic, since the proportion of individuals with chronic
HIV infection in a population often greatly exceeds the proportion
of individuals with recent HIV infection [12].
In low-income countries, surveillance of HIV incidence is often
performed in maternal-child health clinics using serologic assays.
Furthermore, cohorts of HIV seroconverters who are followed
over time to determine the window periods and misclassification
rates of HIV incidence assays may include women who either are
or become pregnant during the observation periods. Pregnancy is
associated with changes in the mother’s immune system. While
earlier studies suggested that pregnancy was associated with
immunosuppression, more recent studies indicate that the
mother’s immune responses during pregnancy are actively
engaged in processes related to conception, embryo implantation,
and development of the placenta [13,14]. While pregnancy does
not generally influence the performance of serologic assays, the
impact of pregnancy on the performance of serologic assays for
HIV incidence determination has not been investigated. Changes
in the dynamics of HIV infection and HIV RNA levels have been
observed during pregnancy, which could also potentially influence
the immunologic response to HIV infection [15]. For these
reasons, we felt it was important to evaluate whether results
obtained using the BED and antibody avidity assays are influenced
by pregnancy.
Materials and Methods
Plasma samples were obtained from Ugandan women who were
enrolled in the HIV Network for Prevention Trials (HIVNET) 012
clinical trial. That trial compared the effectiveness of two regimens
for prevention of mother-to-child transmission of HIV: a single
dose nevirapine regimen and a short course zidovudine regimen
[16]. A subset of women of the HIVNET 012 trial were
subsequently enrolled in a 5-year follow-up study (the Extended
Mother and Child Follow-up; Amendment II for HIVNET 012)
[17]. Samples analyzed in this sub-study were obtained from 51
women in the HIVNET 012 follow-up study who were originally
enrolled in the nevirapine arm of the HIVNET 012 trial and were
stored at 280uC prior to testing. These women were infected with
subtype A (N=29), C (N=1), D (N=16) or intersubtype
recombinant HIV (N=4); the subtype could not be determined
for one woman [18]. One-hundred thirty five plasma samples were
available from the 51 women that were collected during the
HIVNET 012 follow-up study: 44 samples from the 3-year visit, 48
samples from the 4-year visit, and 43 samples from the 5-year visit.
For this sub-study, women were considered to have been pregnant
for 9 months preceding a documented delivery in the follow-up
period. The available sample set included 20 samples collected
from 19 women who were pregnant at the time of sample
collection during the follow-up study. Thirty-seven of the 51
women also had a baseline sample available, collected at the time
of delivery or 7 days after delivery in the HIVNET 012 trial.
The BED assay was performed according to the manufacturer’s
instructions (Calypte Biomedical Corporation, Lake Oswego, OR,
USA), using an assay cut-off of 0.8 normalized optical density units
(OD-n) for recent infection (3). The avidity assay is a modified
version of the Genetic Systems HIV-1/HIV-2+ O EIA (enzyme
linked immunoassay, Bio-Rad Laboratories, Redmond, WA. The
avidity assay was performed as previously described [6,9], except
that an assay cut-off of 40% was used for recent infection.
Generalized estimating equations were used to assess pregnancy
as a predictor of OD-n levels in the BED assay. Differences in
avidity assay between samples from pregnant and non-pregnant
women were assessed using the non-parametric Wilcoxon rank
sum test. A paired t-test was used to compare mean levels of OD-n
from the BED assay among women with both pregnancy and non-
pregnancy samples.
Informed written consent was obtained from all women for
participation in the HIVNET 012 trial. Guidelines of the U.S.
Dept. of Health and Human Services and the authors’ institutions
were followed in the conduct of this research. Approval for this
research was obtained from the Institutional Review Boards in
Uganda and at the Johns Hopkins University School of Medicine.
Results
We examined whether pregnancy influenced results obtained
with the BED and avidity assays. BED and avidity test results were
obtained on 135 samples collected during the HIVNET 012
follow-up study (obtained 3-, 4-, and 5-years following delivery in
HIVNET 012, see Methods). Twenty of the 135 results were
obtained at study visits where a woman was pregnant (Figure 1);
two of these results were obtained from the same woman who
became pregnant twice during the HIVNET 012 follow-up study
(Figure 1, #12). There was no evidence to suggest that the optical
density values obtained with the BED assay when women were
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women were not pregnant (n=115, p=0.9, generalized estimat-
ing equations model). All but four of the avidity index values,
including all values obtained for samples collected when women
were pregnant, were in a very narrow range (between 98.4% and
101.7%); four samples collected when women were not pregnant
had values between 68.0% and 78.1%. There was no evidence for
a difference in avidity test results when women were vs. were not
pregnant (p=0.7, Wilcoxon rank sum). In addition, BED and
avidity results were almost exactly the same in longitudinal
samples from the 18 women who were pregnant at only one study
visit during the follow-up study (p=0.6, paired t-test).
We also compared results obtained at baseline (at or 7 days after
delivery in the HIVNET 012 trial) to results obtained 3–5 years
later (at the follow-up visits). Baseline samples tested as non-recent
with the BED and avidity assays for 32 of the 37 women; five
women had baseline results from the BED and/or avidity assays
that were consistent with recent HIV infection (BED only: #1,
#7, #8; avidity only: #6; both assays: #5). For four of those five
women, test results obtained at follow-up visits were consistent
with chronic HIV infection, suggesting that those four women
were recently infected at the time of delivery in the HIVNET 012
trial. Of note, only one of the four women had an infant who was
HIV-infected at 6 weeks of age (#8). In contrast, BED results from
Figure 1. *Longitudinal samples from women in the HIV Prevention Trials Network (HIVNET) 012 trial and HIVNET 012 follow-up
study were analyzed using the BED-Capture enzyme immunoassay (BED) [8] and an antibody avidity assay based on the BioRad
1/2 + O ELISA test (avidity) [9]. Baseline samples were collected near the time of delivery in the HIVNET 012 trial. Data from the baseline samples is
shaded, as well as data from follow-up visits where a woman was pregnant (see Methods). Results from the BED and avidity assays that indicate
recent infection (BED: results OD-n,0.8; for avidity: results ,40%) are shown in bold text. Results are shown for baseline samples (obtained in the
HIVNET 012 trial from the time of delivery or 7 days after delivery), and for samples collected 3, 4, and 5 years later (3Y, 4Y, 5Y).
aThese women were
identified as falsely incident at follow-up using the BED assay; two of these women had subtype A infection and two had subtype D infection.
bThese
women may have had incident infection in the HIVNET 012 trial.
cThese samples were obtained when women were on antiretroviral therapy.
doi:10.1371/journal.pone.0013259.g001
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recent HIV infection, even though the follow-up samples were
collected 3–5 years after documentation of HIV infection were
misclassified by the BED assay (i.e., results from follow-up samples
from this woman tested as recent). False recent results were
obtained by the BED assay for three other women who did not
have baseline samples available for testing (#2, #3, #4). The four
women who had samples that were misclassified as recent by the
BED assay (#1–4, 11 samples) included two women with subtype
A and two women with subtype D HIV infection. None of the
follow-up samples tested in this study were misclassified as recent
by the avidity assay. Based on testing of the 135 samples collected
at the 3–5 year follow-up visits (i.e., in women known to have been
infected for at least 3 years), 47 (92.2%) of the 51 women were
correctly classified as non-recent by both assays. Three women
(#8, #21, #33) initiated ARV therapy during the follow-up study;
initiation of treatment did not appear to affect BED or avidity test
results (Figure 1).
Discussion
Many epidemiologic studies of HIV surveillance are conducted
in maternal-child health clinics. Other studies suggest that
pregnancy may modulate the immune response to infectious
diseases [19]. In this study, we did not observe an effect of
pregnancy on results obtained with the BED assay or an avidity
assay. With the distribution of BED test results and sample size in
this study, only mean differences between results obtained when
women were vs. were not pregnant that exceeded an optical
density of 0.37 OD-n would have achieved statistical significance
(the minimum margin for non-inferiority). While we did not have
the power to detect small differences in BED test results, given the
range of optical density values observed in pregnancy, there was
nothing to suggest that pregnancy would lead to misclassification
of samples from chronically-infected women as recent. One
limitation of this study is that it was performed using samples
collected years earlier, and some of those samples were previously
thawed and refrozen for other work. In a previous study, we found
no change in BED or avidity assay results when samples were
subjected up to 15 freeze-thaws, or were stored at up to 25uC for
up to 15 days prior to testing [20]. Therefore, issues related to
sample handling and storage of the specimens are not likely to
have influenced the results obtained in this study.
The BED and avidity assay results did not change dramatically
when three women initiated ARV therapy during the follow-up
study. Other studies have shown that ARV therapy can affect
results obtained with antibody-titer-based assays, leading to
misclassification of samples from chronically infected individuals
as recent [21,22]. The three women in this study initiated ARV
therapy shortly before the 5-year visit (only 5 days, 2 months, and
8 months before the visit) and therefore may not have been
virologically suppressed at the time of testing. The BED assay
misclassified follow-up samples from four (7.8%) of the 51 women
in this study as recent, even though HIV infection was
documented 3–5 years before the samples were collected; in
contrast, the avidity assay did not misclassify any of the follow-up
samples as recent. Misclassification of some samples as recent by
the BED assay has been documented in previous studies [22,23].
Interestingly, when a woman’s samples were misclassified by BED,
the misclassification was consistent over the duration of the follow-
up study. Furthermore, the OD-n values (data from the BED
assay) were almost identical during the period of follow-up for all
51 women (median standard deviation: 0.09, interquartile range:
0.06, 0.17). The stability of these values suggests each woman may
reach an immunologic threshold and that the proportion of
antibody that is HIV-specific and the avidity of anti-HIV
antibodies may remain constant in many individuals for extended
periods during HIV infection. Data from other studies suggests
that the anti-HIV antibody response often declines when the virus
is suppressed by ARV treatment or the immune system collapses
in advanced HIV disease [10].
Finally, four women in this study had baseline BED and/or
avidity test results that were consistent with recent HIV infection,
and had follow-up test results consistent with chronic infection;
those women may have been recently HIV-infected at the time of
delivery in the HIVNET 012 trial. Only one of the four women
transmitted HIV to her infant by 6 weeks of age. Further studies
are needed to evaluate the relationship between recent HIV
infection and mother-to-child transmission of HIV.
This sub-study was focused on the impact of pregnancy on the
performance of the BED and avidity assays for cross-sectional HIV
incidence determination. It should be noted that aside from assay
misclassification, another critically important issue with cross-
sectional HIV incidence determination is the whether the samples
are representative of the population of interest. For example,
samples drawn principally from voluntary testing and counseling
centers may not be representative of the broader target
population. In this regard, weighting of the samples to better
reflect the target population may be helpful. The approach used
by the U.S. Centers for Disease Control and Prevention (CDC) for
HIV incidence determination is based on testing samples collected
from HIV/AIDS surveillance systems with the BED assay [24].
The CDC attempted to improve the representativeness of those
tested samples through statistical weighting [24,25]. The CDC also
determined HIV incidence with another approach, extended
back-calculation, which uses surveillance reports on both AIDS
cases and HIV diagnoses [24]. The CDC used these two different
independent approaches to measure HIV incidence in order to
corroborate findings because of the uncertainties with both
approaches.
The results from this study are reassuring; they suggest that any
changes in the antibody response to HIV infection that may occur
during pregnancy are not sufficient to alter results obtained with
the BED and avidity assays. These results indicate that pregnancy
is unlikely to be a significant factor contributing to the
misclassification of chronically-infected individuals as recently
infected that has been observed with these assays. Some studies
suggest that changes in HIV dynamics that occur during
pregnancy may differ among women of different races [15];
therefore, a woman’s race could theoretically affect the level or
quality of anti-HIV antibodies and the performance of serologic
assays for HIV incidence determination during pregnancy. The
BED assay includes subtype D target antigens, but does not
include subtype A antigens. In this limited study, HIV subtype was
not associated with misclassification by the BED assay; two of the
women who were misclassified by the BED assay had subtype A
infection and two had subtype D infection. Further studies are
needed to define the factors that lead to misclassification with these
and other serologic assays used for HIV incidence determination
and to test whether findings from our study can be generalized to
other populations, including those with different prevalent HIV
subtypes and strains.
Acknowledgments
The authors acknowledge the contributions of Prof. Francis Mmiro to
improving the health of women and infants living with HIV and AIDS.
Prof. Mmiro was the Ugandan Principal Investigator of the HIVNET 012
trial. The authors also thank the HIVNET 012 study team, and the women
Pregnancy and Incidence Tests
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13259and infants in these studies, and the staff in Uganda and JHU who assisted
with sample processing.
Disclaimer
The findings and conclusions in this article are those of the authors and
do not necessarily represent the views of the U.S. Centers for Disease
Control and Prevention. Use of trade names is for identification purposes
only and does not constitute endorsement by the U.S. Centers for Disease
Control and Prevention or the Department of Health and Human
Services.’’
Author Contributions
Conceived and designed the experiments: OL JDC SE. Performed the
experiments: OL AEO. Analyzed the data: AM DD RB. Contributed
reagents/materials/analysis tools: SMO RB PM JBJ LG CN. Wrote the
paper: OL JDC AEO AM SMO DD RB PM JBJ LG CN TQ SE.
References
1. Brookmeyer R (2010) Measuring the HIV/AIDS epidemic: approaches and
challenges. Epidemiol Rev 32: 26–37.
2. Hallett TB, Zaba B, Todd J, Lopman B, Mwita W, et al. (2008) Estimating
incidence from prevalence in generalised HIV epidemics: methods and
validation. PLoS Med 5: e80.
3. Brookmeyer R, Quinn TC (1995) Estimation of current human immunodefi-
ciency virus incidence rates from a cross-sectional survey using early diagnostic
tests. Am J Epidemiol 141: 166–172.
4. Murphy G, Parry JV (2008) Assays for the detection of recent infections with
human immunodeficiency virus type 1. Euro Surveill 13. pii 18966.
5. Guy R, Gold J, Calleja JM, Kim AA, Parekh B, et al. (2009) Accuracy of
serological assays for detection of recent infection with HIV and estimation of
population incidence: a systematic review. Lancet Infect Dis 9: 747–759.
6. Laeyendecker O, Rothman RE, Henson C, Horne BJ, Ketlogetswe KS, et al.
(2008) The effect of viral suppression on cross-sectional incidence testing in the
Johns Hopkins Hospital Emergency Department. J Acquir Immune Defic Syndr
48: 211–215.
7. Young CL, Hu DJ, Byers R, Vanichseni S, Young NL, et al. (2003) Evaluation
of a sensitive/less sensitive testing algorithm using the bioMerieux Vironostika-
LS assay for detecting recent HIV-1 subtype B’ or E infection in Thailand. AIDS
Res Hum Retroviruses 19: 481–486.
8. Dobbs T, Kennedy S, Pau CP, McDougal JS, Parekh BS (2004) Performance
characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an
assay to detect recent human immunodeficiency virus type 1 seroconversion.
J Clin Microbiol 42: 2623–2628.
9. Masciotra S, Candal D, Hanson D, Delaney K, Rudolph D, et al. (2010)
Antibody avidity-based assay for identifying recent HIV-1 infections based on
GeneticSystems TM K plus O EIA. 17th Conf on Retroviruses and
Opportunistic Infections. San Francisco, CA.
10. Marinda ET, Hargrove J, Preiser W, Slabbert H, van Zyl G, et al. Significantly
diminished long-term specificity of the BED capture enzyme immunoassay
among patients with HIV-1 with very low CD4 counts and those on
antiretroviral therapy. J Acquir Immune Defic Syndr 53: 496–499.
11. Laeyendecker O, Oliver A, Neal J, Gamiel J, Kraus C, et al. (2009) Decreasing
HIV incidence and prevalence at the Johns Hopkins Emergency Department
with a concurrent increase of virally-suppressed HIV-infected individuals. 16th
Conference on Retroviruses and Opportunistic Infections. Montreal, Quebec,
Canada.
12. Welte A, McWalter TA, Laeyendecker O, Hallett TB. Using tests for recent
infection to estimate incidence: problems and prospects for HIV. Euro Surveill
15, pii19589.
13. Robertson SA (2010) Immune regulation of conception and embryo implanta-
tion-all about quality control? J Reprod Immunol 85: 51–57.
14. Piccinni MP (2010) T cell tolerance towards the fetal allograft. J Reprod
Immunol 85: 71–75.
15. Patel D, Thorne C, Newell ML, Cortina-Borja M (2009) Levels and patterns of
HIV RNA viral load in untreated pregnant women. Int J Infect Dis 13: 266–273.
16. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, et al. (1999) Intrapartum
and neonatal single-dose nevirapine compared with zidovudine for prevention of
mother-to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET-012
randomised trial. Lancet 354: 795–802.
17. Flys TS, Mwatha A, Guay LA, Nakabiito C, Donnell D, et al. (2007) Detection
of K103N in Ugandan women after repeated exposure to single dose nevirapine.
AIDS 21: 2077–2082.
18. Eshleman SH, Guay LA, Mwatha A, Brown ER, Cunningham SP, et al. (2004)
Characterization of nevirapine resistance mutations in women with subtype A
vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir
Immune Defic Syndr 35: 126–130.
19. Jamieson DJ, Theiler RN, Rasmussen SA (2006) Emerging infections and
pregnancy. Emerg Infect Dis 12: 1638–1643.
20. Laeyendecker O (2009) BED+ avidity testing algorithm for incidence estimates
in Uganda (PowerPoint presentation). Session II: Measuring new HIV infections;
where we are with new technologies and approaches measuring HIV incidence
The 2nd Global HIV/AIDS Surveillance Meeting Bangkok, Thailand.
21. Laeyendecker O, Oliver A, Neal J, Gamiel J, Kraus C, et al. (2009) Decreasing
HIV incidence and prevalence at the Johns Hopkins Emergency Department
with a concurrent increase of virally-suppressed HIV-infected individuals;
Montreal, Quebec, Canada.
22. Martro E, Suligoi B, Gonzalez V, Bossi V, Esteve A, et al. (2005) Comparison of
the avidity index method and the serologic testing algorithm for recent human
immunodeficiency virus (HIV) seroconversion, two methods using a single serum
sample for identification of recent HIV infections. J Clin Microbiol 43:
6197–6199.
23. UNAIDS Reference Groupon Estimates and Projections. (2006) Statement on
the use of the BED assay for the estimation of HIV-1 incidence for surveillance
or epidemic monitoring. Wkly Epidemiol Rec 81: 40.
24. Hall HI, Song R, Rhodes P, Prejean J, An Q, et al. (2008) Estimation of HIV
incidence in the United States. JAMA 300: 520–529.
25. Karon JM, Song R, Brookmeyer R, Kaplan EH, Hall HI (2008) Estimating HIV
incidence in the United States from HIV/AIDS surveillance data and biomarker
HIV test results. Stat Med 27: 4617–4633.
Pregnancy and Incidence Tests
PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13259